Aspirin does not influence the effect of angiotensin-converting enzyme inhibition on left ventricular ejection fraction 3 months after acute myocardial infarction

European Journal of Heart Failure

Volumn 3, Issue 2, 2001, Pages 203-207

  Hurlen, Mette ^a   Hole, Torstein ^b   Seljeflot, Ingebjørg ^a   Arnesen, Harald ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b Møre and Romsdal Health Trust   (Norway)

Author keywords

Angiotensin converting enzyme inhibitor; Aspirin; Interaction; Left ventricular ejection fraction; Myocardial infarction

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ACETYLSALICYLIC ACID; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN 1; LISINOPRIL; RENIN; THROMBOXANE B2; WARFARIN;

ACUTE HEART INFARCTION; ANTICOAGULATION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG CROSS REACTIVITY; DRUG MECHANISM; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; TREATMENT OUTCOME;

EID: 0035107343     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(00)00138-0     Document Type: Article

References (28)

1. Effects of enalapril on mortality in severe congestive heart failure
2. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
3. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure
4. Vasopressin, renin, and norepinephrine levels before and after captopril administration in patients with congestive heart failure due to idiopathic dilated cardiomyopathy
5. Basic pharmacology of ACE-inhibitors with respect to ischaemic heart disease: Prostaglandins and bradykinin
6. Converting enzyme inhibitors and the interaction between kinins and eicosanoids
7. Collaborative overview of randomized trials of antiplatelet therapy. (I) Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients
8. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients
9. A prostacyclin-sparing effect of indobufen vs. aspirin
10. Studies of left ventricular dysfunction (SOLVD): Subgroup results
11. Effect of ramipril on mortality and morbidity of survivors of acute myocardinal infarction with clinical evidence of heart failure
12. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: Subgroup analysis of the co-operative new scandinavian enalapril survival study II (Consensus II)
13. Meeting report-the LIDO, HOPE, MEXCON and WASH studies
14. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure
15. Effects of acetylsalicylic acid on peripheral hemodynamics in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors
16. The absence of a pharmacokinetic interaction between aspirin and the angiotensin-converting enzyme inhibitor benazepril in healthy volunteers
17. Combining salicylate and enalapril in patients with coronary artery disease
18. Peripheral hemodynamic effects of captopril in patients with congestive heart failure
19. Improvement of alveolar-capillary membrane diffusing capacity with enalapril in chronic heart failure and counteracting effect of aspirin
20. Effects of warfarin, aspirin and the two combined on mortality and thrombo-embolic morbidity after myocardial infarction. The WARIS-II study design
21. Nuclear cardiology
22. Preventive treatment of asymptomatic left ventricular dysfunction following myocardial infarction
23. Effects of early captopril administration on infarct expansion, left ventricular remodeling and exercise capacity after acute myocardial infarction
24. Identification and plasma concentrations of the N-terminal fragment of proatrial natriuretic factor in man
25. Selective inhibition of platelet cyclooxygenase with controlled release, low dose aspirin
26. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin
27. Effects of ACE inhibition on spontaneous and insulin-stimulated endothelin-1 secretion
28. Plasma endothelin-1 in acute myocardial infarction with heart failure